Artelo Biosciences (ARTL) to Release Quarterly Earnings on Wednesday

Artelo Biosciences (NASDAQ:ARTL) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.72) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Thursday, May 14th. The company reported ($4.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($3.22).

Artelo Biosciences Price Performance

Shares of ARTL opened at $0.77 on Wednesday. Artelo Biosciences has a 1-year low of $0.71 and a 1-year high of $31.65. The stock has a market cap of $1.78 million, a PE ratio of -0.02 and a beta of -0.07. The firm has a fifty day moving average price of $1.15 and a 200 day moving average price of $3.27.

Analysts Set New Price Targets

Several equities analysts have issued reports on ARTL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artelo Biosciences in a report on Wednesday, June 24th. Wall Street Zen raised Artelo Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.